HR+ Breast Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

NiKang Therapeutics
NiKang TherapeuticsDE - Wilmington
1 program
1
NKT5097 CDK2/CDK4 dual degraderPhase 11 trial
Active Trials
NCT07029399Recruiting205Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
NiKang TherapeuticsNKT5097 CDK2/CDK4 dual degrader

Clinical Trials (1)

Total enrollment: 205 patients across 1 trials

NCT07029399NiKang TherapeuticsNKT5097 CDK2/CDK4 dual degrader

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Start: Mar 2025Est. completion: Dec 2027205 patients
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 205 patients
1 companies competing in this space